Cross-Market Price Comparison
| Other Listed Market | To be extracted |
|---|---|
| Other Market Stock Code | To be extracted |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | CMS |
|---|---|
| Stock Code | 00867 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家立足於中國的領先醫藥服務公司,專門從事營銷、推廣及銷售國內外專業製藥公司的處方藥品,提供獨家營銷、推廣及銷售服務,包括一對一拜訪醫生、舉辦醫學研討會和贊助行業會議等。 |
| Listing Date | 2010-09-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國深圳市南山區深圳高新科技園北區朗山路11號同方信息港A棟6樓、8樓 郵編518057 |
| Business Address (Hong Kong) | 香港北角英皇道510號港運大廈21樓2106室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.cms.net.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | Yes (AIM) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 5.06 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 800 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2010-09-20 to 2010-09-20 |
| Global Offering Shares | 200,000,000 shares |
| HK Public Offer Shares (Initial) | 20,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 25,000lots (Pool A12,500lots,Pool B12,500lots) |
| International Placing Shares (Initial) | 180,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,123,691,440 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,012,000,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 28.71B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约20.8百万美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 54,100,000 |
| Listing Expenses / Funds Raised | ~5.35% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2007 | 2008 | 2009 | 2010-06 |
|---|---|---|---|---|
| Revenue | 51,747 | 72,600 | 96,454 | 61,195 |
| Cost of sales | -18,149 | -27,835 | -35,596 | -23,970 |
| Gross profit | 33,598 | 44,765 | 60,858 | 37,225 |
| Other income and gains, net | 1,280 | 2,690 | 662 | 546 |
| Selling and distribution expenses | -13,934 | -18,631 | -24,840 | -13,318 |
| Administrative expenses | -5,947 | -6,940 | -7,399 | -3,274 |
| Net finance costs | -301 | -226 | -390 | -336 |
| Share of associates and JVs | 56 | 152 | 30 | 42 |
| Profit before tax | 10,346 | 19,535 | 26,926 | 19,689 |
| Income tax expense | -1,672 | -4,487 | -6,096 | -4,355 |
| Profit for the year | 8,674 | 15,048 | 20,830 | 15,334 |
| Profit attributable to owners | 8,685 | 14,946 | 20,684 | 15,230 |
Balance Sheet
| Item | 2007 | 2008 | 2009 | 2010-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 17,601 | 20,100 | 15,113 | 10,340 |
| Trade and bills receivables | 19,305 | 27,684 | 32,794 | 41,485 |
| Inventories | 10,677 | 5,945 | 11,060 | 17,437 |
| Total current assets | 47,767 | 55,004 | 77,120 | 88,308 |
| Total assets | 41,844 | 59,739 | 60,989 | 72,229 |
| Total current liabilities | 13,100 | 10,755 | 29,788 | 31,371 |
| Total equity | 41,844 | 52,721 | 53,934 | 64,954 |
| Equity attributable to owners | 42,000 | 52,790 | 53,733 | 64,954 |
| Interest-bearing borrowings | 0 | 0 | 16,517 | 16,346 |
Cash Flow Statement
| Item | 2007 | 2008 | 2009 | 2010-06 |
|---|---|---|---|---|
| Net cash from operating activities | 6,572 | 10,175 | 15,549 | 4,673 |
| Net cash from investing activities | -1,861 | -1,744 | -16,616 | -2,812 |
| Net cash from financing activities | 3,072 | -7,219 | -4,022 | -6,937 |
| Net increase in cash | 7,783 | 1,212 | -5,089 | -5,076 |
| Depreciation of PP&E | 637 | 772 | 898 | 380 |
| Amortisation of intangible assets | 59 | 793 | 1,115 | 419 |
| Purchase of PP&E | -795 | -959 | -280 | -101 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 5.64 |
|---|---|
| First Day Open | HK$ 5.85 |
| First Day Change | 11.46% |
| First Day Volume | 211863000.0 |
| First Day Turnover | 1255170000.0 |
| Use of Proceeds | 1、約8.3%或67.5百萬港元,將用于通過聘請更多合資格及專業員工及擴大醫院覆蓋范圍和地域范圍;
2、約12.5%或101.7百萬港元,將用于興建新培訓及會議中心以供進行醫生培訓、醫學會議及其他推廣活動以及員工培訓;
3、約8.3%或67.5百萬港元,將用于更換、改善或升級信息管理系統的軟硬件;
4、約33.3%或270.9百萬港元,將用于收購在中國推廣銷售藥品的獨家授權及尋求并購合適制藥公司的機會。
5、在取得理想的CMS024臨床進展后,約16.8%或136.7百萬港元,將用于興建一個生產廠房以供制造公司自行生產的藥品。
6、約10%或87.8百萬港元,將用于撥款向供應商采購進口藥品以滿足中國市場對我們的授權引進產品日益增加的需求;
7、約10%或81.3百萬港元,將用作我們的營運資金及其他一般企業用途; |
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (1)
UBS Securities Hong Kong Limited CE BIN466
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 林剛 | — |
| Company Secretary | 許永善 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 林剛(46.39%) |
|---|




